Genentech submits sBLA for Avastin’s use in glioblastoma treatment
Genentech, Inc. has submitted an application to the U.S. Food and Drug Administration for its product Avastin® as a therapy for patients of glioblastoma who have received a treatment previously. If the supplemental Biologics License Application (sBLA) is accepted by the FDA, the drug can be considered for a provisional approval for treatment of cancer and other such deadly diseases. Glioblastoma is the most aggressive form of brain cancer. It has no cure. The study found that Avastin, when as evaluated as a single agent, showed that 43 percent of patients experienced no progression of disease.

The U.S. Food and Drug Administration has given the approval to
The U.S. Food and Drug Administration has cleared US Spine’s Preference 2 Complex Spine System™ for use in the United States. With this approval,
The U.S. Food and Drug Administration has approved
The U.S. Food and Drug Administration has approved
The FDA has approved the first generic versions of
The FDA has granted approval for the Abbreviated New Drug Application (ANDA) filed by
GlaxoSmithKline said that clinical trials of Treximet indicate that the drug provided migraine relief at two hours for a significantly greater percentage of patients than Imitrex 85 mg or naproxen sodium 500 mg alone.